Live Breaking News & Updates on Relational Commerce

Stay updated with breaking news from Relational commerce. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Revance to Host Investor Day on September 19, 2023

Revance Therapeutics, Inc. today announced that the company will host an Investor Day on September 19, 2023, from 9:30 AM ET to 1:00 PM ET.

Interested parties can attend the live webcast for the. ....

Revance Therapeutics Inc , Viatris Inc , Revance Therapeutics , Investor Day , Investor Relations , Relational Commerce , Shanghai Fosun Pharmaceutical , Resilient Hyaluronic Acid ,

U.S. FDA Approves First Therapeutic Indication for Revance's DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

- Provides Revance entry into the $2.5 billion U.S. therapeutic neuromodulator market.1

- Approval expands the DAXXIFY® label to include efficacy data over the 52-week ASPEN repeat dose clinical.
-Today at 08:04 am- MarketScreener ....

United States , Markj Foley , Peter Mcallister , Association Of Academic Physiatrists Annual Meeting , Peptide Exchange Technology , Revance Therapeutics Inc , American Academy Of Physical Medicine , Securities Exchange , Dystonia Medical Research Foundation , Drug Administration , Exchange Commission , England Institute For Neurology , Hint Inc , Viatris Inc , Revance Therapeutics , Chief Executive Officer Mark , New England Institute , Label Study , Boxed Warning , Distant Spread , Specific Populations , Prescribing Information , Relational Commerce , Shanghai Fosun Pharmaceutical , Resilient Hyaluronic Acid , Private Securities Litigation Reform Act ,

Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update

- Q2 total revenue of $58.1 million, a YoY increase of 104.9%.- Q2 RHA® Collection revenue of $31.8 million, a YoY increase of 24.7%.- Q2 DAXXIFY® revenue of $22.6 million, a QoQ increase of 47.1%.- Bolstered financial position with $100 million net proceeds from ATM program and $50 million in notes available to be. ....

United States , Jessica Serra , Fosun Pharma , Laurence Watts , Markj Foley , China National Medical Products Administration , Securities Exchange , Gilmartin Group , Viatris Inc , Revance Therapeutics Inc , Hint Inc , Drug Administration , Exchange Commission , Athyrium Capital , Revance Therapeutics , Note Purchase Agreement , Second Tranche , Third Tranche , Chief Executive Officer , Investor Day , Quarter Highlights , Relational Commerce , National Medical Products Administration , Hyaluronic Acid , Private Securities Litigation Reform Act , Securities Act ,

Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update

- Q2 total revenue of $58.1 million, a YoY increase of 104.9%.
- Q2 RHA® Collection revenue of $31.8 million, a YoY increase of 24.7%.
- Q2 DAXXIFY® revenue of $22.6 million, a QoQ increase of. ....

United States , Fosun Pharma , Markj Foley , Securities Exchange , China National Medical Products Administration , Viatris Inc , Drug Administration , Revance Therapeutics Inc , Hint Inc , Exchange Commission , Revance Therapeutics , Athyrium Capital , Note Purchase Agreement , Second Tranche , Third Tranche , Chief Executive Officer , Investor Day , Quarter Highlights , Relational Commerce , National Medical Products Administration , Hyaluronic Acid , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Consolidated Statements , Months Ended June ,

Revance to Participate in Upcoming Investor Conferences

Revance Therapeutics, Inc. today announced that the company will be participating in the following investor conferences.

William Blair 43rd Annual Growth Stock Conference

Chief Executive Officer. | May 23, 2023 ....

Dana Point , United States , Dustins Sjuts , William Blair , Markj Foley , Goldman Sachs , Revance Therapeutics Inc , Viatris Inc , Revance Therapeutics , Annual Growth Stock , Executive Officer Mark , Annual Global Healthcare , President Dustin , Investor Relations , Relational Commerce , Hyaluronic Acid , Nc Stock Exchange , Press Release , Xecutive Rvnc Us7613301099 ,